Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176225573> ?p ?o ?g. }
- W3176225573 abstract "Abstract Background Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the currently recommended first- and second-line therapies for uncomplicated Plasmodium falciparum infections in Equatorial Guinea. This study was designed to evaluate the efficacy of these artemisinin-based combinations and detect mutations in P. falciparum kelch13 -propeller domain gene ( Pfkelch13 ). Methods A single-arm prospective study evaluating the efficacy of ASAQ and AL at three sites: Malabo, Bata and Ebebiyin was conducted between August 2017 and July 2018. Febrile children aged six months to 10 years with confirmed uncomplicated P. falciparum infection and other inclusion criteria were sequentially enrolled first in ASAQ and then in AL at each site, and followed up for 28 days. Clinical and parasitological parameters were assessed. The primary endpoint was PCR-adjusted adequate clinical and parasitological response (ACPR). Samples on day-0 were analysed for mutations in Pfkelch13 gene. Results A total 264 and 226 patients were enrolled in the ASAQ and AL treatment groups, respectively. Based on per-protocol analysis, PCR-adjusted cure rates of 98.6% to 100% and 92.4% to 100% were observed in patients treated with ASAQ and AL, respectively. All study children in both treatment groups were free of parasitaemia by day-3. Of the 476 samples with interpretable results, only three samples carried non-synonymous Pfkelch13 mutations (E433D and A578S), and none of them is the known markers associated with artemisinin resistance. Conclusion The study confirmed high efficacy of ASAQ and AL for the treatment of uncomplicated falciparum infections as well as the absence of delayed parasite clearance and Pfkelch13 mutations associated with artemisinin resistance. Continued monitoring of the efficacy of these artemisinin-based combinations, at least every two years, along with molecular markers associated with artemisinin and partner drug resistance is imperative to inform national malaria treatment policy and detect resistant parasites early. Trial registration ACTRN12617000456358, Registered 28 March 2017; http://www.anzctr.org.au/trial/MyTrial.aspx" @default.
- W3176225573 created "2021-07-05" @default.
- W3176225573 creator A5000519005 @default.
- W3176225573 creator A5010465638 @default.
- W3176225573 creator A5014087860 @default.
- W3176225573 creator A5021882759 @default.
- W3176225573 creator A5037045331 @default.
- W3176225573 creator A5049427727 @default.
- W3176225573 creator A5050036548 @default.
- W3176225573 creator A5054836364 @default.
- W3176225573 creator A5057932399 @default.
- W3176225573 creator A5063262771 @default.
- W3176225573 creator A5073848974 @default.
- W3176225573 creator A5079567219 @default.
- W3176225573 creator A5080439867 @default.
- W3176225573 creator A5089765631 @default.
- W3176225573 creator A5090394978 @default.
- W3176225573 date "2021-06-22" @default.
- W3176225573 modified "2023-10-12" @default.
- W3176225573 title "Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea" @default.
- W3176225573 cites W1870326007 @default.
- W3176225573 cites W2102395543 @default.
- W3176225573 cites W2103439634 @default.
- W3176225573 cites W2104700616 @default.
- W3176225573 cites W2124634096 @default.
- W3176225573 cites W2129428401 @default.
- W3176225573 cites W2142960482 @default.
- W3176225573 cites W2149845722 @default.
- W3176225573 cites W2163924699 @default.
- W3176225573 cites W2171102256 @default.
- W3176225573 cites W2178461653 @default.
- W3176225573 cites W2228511309 @default.
- W3176225573 cites W2425623382 @default.
- W3176225573 cites W2467259677 @default.
- W3176225573 cites W2579721738 @default.
- W3176225573 cites W2584480708 @default.
- W3176225573 cites W2590767446 @default.
- W3176225573 cites W2595820219 @default.
- W3176225573 cites W2609143407 @default.
- W3176225573 cites W2785409899 @default.
- W3176225573 cites W2802043998 @default.
- W3176225573 cites W2805309778 @default.
- W3176225573 cites W2809951886 @default.
- W3176225573 cites W2895245324 @default.
- W3176225573 cites W2901544838 @default.
- W3176225573 cites W2922704184 @default.
- W3176225573 cites W2923208923 @default.
- W3176225573 cites W2952468349 @default.
- W3176225573 cites W2959484794 @default.
- W3176225573 cites W2960101348 @default.
- W3176225573 cites W2963076417 @default.
- W3176225573 cites W2996445813 @default.
- W3176225573 cites W3001008900 @default.
- W3176225573 cites W3031413726 @default.
- W3176225573 cites W3046809066 @default.
- W3176225573 doi "https://doi.org/10.1186/s12936-021-03807-x" @default.
- W3176225573 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8220721" @default.
- W3176225573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34158055" @default.
- W3176225573 hasPublicationYear "2021" @default.
- W3176225573 type Work @default.
- W3176225573 sameAs 3176225573 @default.
- W3176225573 citedByCount "7" @default.
- W3176225573 countsByYear W31762255732021 @default.
- W3176225573 countsByYear W31762255732022 @default.
- W3176225573 countsByYear W31762255732023 @default.
- W3176225573 crossrefType "journal-article" @default.
- W3176225573 hasAuthorship W3176225573A5000519005 @default.
- W3176225573 hasAuthorship W3176225573A5010465638 @default.
- W3176225573 hasAuthorship W3176225573A5014087860 @default.
- W3176225573 hasAuthorship W3176225573A5021882759 @default.
- W3176225573 hasAuthorship W3176225573A5037045331 @default.
- W3176225573 hasAuthorship W3176225573A5049427727 @default.
- W3176225573 hasAuthorship W3176225573A5050036548 @default.
- W3176225573 hasAuthorship W3176225573A5054836364 @default.
- W3176225573 hasAuthorship W3176225573A5057932399 @default.
- W3176225573 hasAuthorship W3176225573A5063262771 @default.
- W3176225573 hasAuthorship W3176225573A5073848974 @default.
- W3176225573 hasAuthorship W3176225573A5079567219 @default.
- W3176225573 hasAuthorship W3176225573A5080439867 @default.
- W3176225573 hasAuthorship W3176225573A5089765631 @default.
- W3176225573 hasAuthorship W3176225573A5090394978 @default.
- W3176225573 hasBestOaLocation W31762255731 @default.
- W3176225573 hasConcept C126322002 @default.
- W3176225573 hasConcept C203014093 @default.
- W3176225573 hasConcept C2776120307 @default.
- W3176225573 hasConcept C2776992834 @default.
- W3176225573 hasConcept C2778048844 @default.
- W3176225573 hasConcept C2778118209 @default.
- W3176225573 hasConcept C2778371730 @default.
- W3176225573 hasConcept C2778629330 @default.
- W3176225573 hasConcept C71924100 @default.
- W3176225573 hasConceptScore W3176225573C126322002 @default.
- W3176225573 hasConceptScore W3176225573C203014093 @default.
- W3176225573 hasConceptScore W3176225573C2776120307 @default.
- W3176225573 hasConceptScore W3176225573C2776992834 @default.
- W3176225573 hasConceptScore W3176225573C2778048844 @default.
- W3176225573 hasConceptScore W3176225573C2778118209 @default.
- W3176225573 hasConceptScore W3176225573C2778371730 @default.
- W3176225573 hasConceptScore W3176225573C2778629330 @default.
- W3176225573 hasConceptScore W3176225573C71924100 @default.